Connect Biopharma

CNTB Lead: Phase 2 2 Biotech Distilled articles ↓

Most recent annual filing: 2026-03-31

Catalyst timeline

Rademikibart atopic dermatitis China decision2H 2026Rademikibart atopic dermatitis China decision, 2H 2026, material
Rademikibart Ph2 toplineSep 2026Rademikibart Ph2 topline, Sep 2026, thesis-defining
Rademikibart filing4Q 2026Rademikibart filing, 4Q 2026, notable

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (4 active programs)

rademikibart

CBP-201

Protein Target: IL-4Rα

Asthma Phase 2 subcutaneous
Asthma Phase 2 intravenous
Chronic Obstructive Pulmonary Disease Phase 2 subcutaneous
Chronic Obstructive Pulmonary Disease Phase 2 intravenous

Discontinued (1)

rademikibart — Atopic Dermatitis · Connect has decided to not currently pursue further development of rademikibart for AD

Biotech Distilled coverage (2)

2026-08-13 UPDATE: Connect Biopharma (CNTB) - The Clock Is Set, The Cushion Is Gone 🔒 Paid
2026-06-08 Connect Biopharma (CNTB) - Scientific Deep Dive for Rademikibart and Pipeline Products

Articles open on Substack. Some deep dives are subscriber-only.